Axsome's phase III FOCUS study, evaluating solriamfetol for treating attention deficit hyperactivity disorder, meets its primary and key secondary...

On TikTok, misinformation about attention-deficit/hyperactivity disorder can be tricky to spot, according to a new study. Read full story

Cassava stock crashes 32% as its investigational Alzheimer's disease drug fails to meet the prespecified co-primary endpoints in the second late-stage...

One of two of Opthea's phase III trials for a common eye disease has failed to meet its primary endpoints, ...

One of two of Opthea's phase III trials for a common eye disease has failed to meet its primary endpoints, ...

UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical significance for the...

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

KUALA LUMPUR: The human resource sector, despite its focus on hiring and retention, experiences a high employee turnover rate, with 21.23 per cent of...

The Overlord of Dagbon, Yaa Naa Abukari II, has called for the commencement of Phase Three of the ongoing airport development project to ensure that...

The Overlord of Dagbon, Yaa Naa Abukari II, has called for the commencement of Phase Three of the ongoing airport development project to ensure that...